September 24, 2025
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ANXV may offer intravenous option for retinal vein occlusion treatment
LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Michael A. Singer, MD, shares the results of a phase 2a trial investigating ANXV, a phosphatidylserine blocker designed to treat retinal vein occlusion
312 words~1 min read
